Why Your Immune System Recognizes HMOs — And What That Means for Gut Health

Your immune system is extraordinarily good at telling self from non-self. It has to be — the consequence of getting it wrong is either uncontrolled infection or autoimmune chaos. What most people don't know is that this discrimination happens not just at the level of proteins and cells, but at the level of carbohydrate structures — the sugar-based molecular language written across nearly every surface of your body.

Human milk oligosaccharides speak this language fluently. And that fluency, it turns out, is the deepest reason why HMOs do something no other prebiotic can replicate.

What Are Blood Group Antigens — and Why Do They Matter Here?

Blood group antigens are carbohydrate structures displayed on the surface of red blood cells and throughout the gut lining. The ABO system you've heard of — A, B, O, AB — is defined entirely by which sugar residues cap these carbohydrate chains. The H-antigen is the core scaffold that all ABO antigens are built on.

These structures are produced by enzymes called fucosyltransferases — specifically FUT1, FUT2, and FUT3. Here's what matters: these are the same enzymes that build fucosylated HMOs.

As landmark HMO researcher Lars Bode documented in his comprehensive review in Glycobiology, 2012 (PMID: 22513036), HMO composition is directly shaped by a mother's secretor status — determined by the FUT2 gene — the same gene that determines whether blood group antigens appear in bodily secretions. HMOs and blood group antigens are built from the same molecular blueprints, by the same enzymatic machinery, in the same body.

This is not coincidence. It is co-evolution.

Why the Gut Immune System Has Receptors for HMO Structures

The gut immune system doesn't inspect every molecule that passes through. It uses pattern recognition — identifying familiar molecular signatures that signal safety, or unfamiliar ones that warrant a response. The receptors responsible for reading carbohydrate structures are called lectins: galectins, siglecs, and C-type lectin receptors (CLRs).

A 2025 landmark review in Frontiers in Immunology by Slater, Hickey, and Davey (PMID: 39877362) mapped exactly how HMOs interact with these receptors across the gut immune system. The findings are remarkable:

• 25 of 31 HMOs tested showed high binding affinity for galectins — endogenous lectin receptors expressed by macrophages, T cells, and dendritic cells.
• Sialylated HMOs bind to siglecs — immune regulatory receptors that specifically recognize sialylated glycan patterns as host-derived structures.
• Fucosylated HMOs interact with DC-SIGN and related C-type lectin receptors expressed on dendritic cells and macrophages — triggering tolerogenic responses.

These are not non-specific interactions. They are structured molecular conversations between HMO carbohydrate motifs and immune receptors that evolved to recognize human-type glycan patterns as self.

No plant fiber does this. Inulin, FOS, GOS — these are polysaccharides the human immune system encounters but carries no dedicated recognition hardware for. They feed bacteria in the colon, which is valuable. But they don't speak the glycan language the immune system reads.

How This Calibrates Immune Tolerance, Not Just the Microbiome

When the gut immune system encounters HMO-like structures, what happens next is more sophisticated than a simple "pass" signal. The Slater et al. 2025 review documents a cascade of immune-modulatory effects that go well beyond microbiome feeding:

HMOs induce tolerogenic dendritic cells. Studies show that 2'-fucosyllactose drives an increase in CD103+ tolerogenic dendritic cells in the mesenteric lymph nodes — the immune gateways of the gut. These tolerogenic DCs are specifically responsible for generating regulatory T cells (Tregs) and promoting gut-homing immune tolerance.

HMOs expand regulatory T cell populations. Pooled HMOs have been shown to increase Treg frequency and IL-10 production, while reducing inflammatory Th1 responses. This is the molecular mechanism behind gut immune calibration — the immune system learns to tolerate harmless dietary antigens and commensal bacteria rather than mounting unnecessary inflammatory reactions.

HMOs attenuate mast cell degranulation. Multiple HMOs reduce histamine release and allergic mediator production from mast cells — a direct anti-hypersensitivity effect that operates independently of the microbiome.

This immune calibration capacity is structurally encoded. It requires HMOs that carry the right molecular shapes — neutral, fucosylated, and sialylated structures — to engage the full range of lectin receptors that govern gut immune tone.

Why Bovine Lactoferrin Is Recognized Differently Than Human Lactoferrin

The same logic applies to lactoferrin — and here the contrast is especially stark.

Human lactoferrin (hLF) and bovine lactoferrin (bLF) share approximately 69% amino acid homology. That 31% divergence matters. But perhaps more important than the amino acid sequence is the glycosylation pattern — the carbohydrate structures attached to the protein.

As documented by Ohradanova-Repic et al. in Pharmaceutics, 2023 (PMID: 37111542), human lactoferrin carries 3 N-glycosylation sites, while bovine lactoferrin carries 5. The structures decorating those sites are also different — hLF displays human-type glycan patterns, while bLF carries bovine-type glycans that the human immune system has no "self-recognition" pathway for.

This means that when bovine lactoferrin arrives at gut immune receptor sites, it presents unfamiliar glycan structures. The immune system registers a foreign-origin protein. This doesn't make bovine lactoferrin harmful — it's been safely consumed for years. But it does mean the interaction is fundamentally different from how the gut handles human lactoferrin, which carries exactly the glycan patterns human immune receptors expect to see.

effera™, the recombinant human lactoferrin in kēpos, is produced to match human lactoferrin's sequence and glycosylation profile. It carries the same 3 N-glycosylation sites, displaying human-type carbohydrate structures. The gut immune system encounters it as self — not as a modified bovine protein.

Why kpHMO™ Matters for This "Immune Fluency"

The immune calibration effects described above are not delivered by a single HMO. They require structural diversity across the three major HMO classes — neutral, fucosylated, and sialylated — because different immune receptors respond to different glycan motifs.

Sialylated HMOs bind siglec receptors on regulatory immune cells. Fucosylated HMOs engage DC-SIGN and C-type lectins. Neutral HMOs, including lacto-N-tetraose, mirror the H-antigen core structure and interact with galectin receptors involved in T cell and dendritic cell signaling.

Most single-HMO supplements provide only one or two of these structures. kpHMO™ — a proprietary ingredient designed and owned exclusively by kēpos — covers all neutral, fucosylated, and sialylated bases, delivering the full structural diversity of real breast milk oligosaccharides. This breadth is what allows the complete immune recognition response — across galectins, siglecs, and C-type lectin receptors simultaneously.

Paired with effera™ human lactoferrin, kēpos delivers both the carbohydrate and the protein components of this immune language. No other adult gut health supplement does this. To learn more about the science behind HMOs and gut immunity, explore the kēpos blog.

What This Means Practically

Understanding why the immune system recognizes HMOs as self isn't just academic. It explains clinical observations that have puzzled researchers who framed HMOs only as prebiotics.

If HMOs were merely feeding Bifidobacterium, you wouldn't expect them to reduce mast cell degranulation in the absence of a functioning microbiome — but they do. You wouldn't expect them to expand Treg populations through direct receptor engagement — but they do. You wouldn't expect them to inhibit selectin-mediated immune cell trafficking independently of bacterial metabolites — but they do.

The answer is that HMOs carry structural information the immune system is designed to read. When that information is complete — when the full spectrum of neutral, fucosylated, and sialylated structures is present — the gut immune system may be more able to maintain the calibration it needs to distinguish real threats from harmless food antigens and commensal bacteria.

This may have practical implications for people dealing with food sensitivities, chronic gut hypersensitivity, or inflammatory conditions where immune over-reactivity in the gut plays a role. HMOs may support immune tolerance — not by suppressing immune function, but by delivering the molecular cues the system needs to remain calibrated.

Frequently Asked Questions

Written by Oliver Drazsky | Sources: Bode L, Glycobiology 2012 (PMID: 22513036); Slater AS et al., Front Immunol 2025 (PMID: 39877362); Ohradanova-Repic et al., Pharmaceutics 2023 (PMID: 37111542)